After over 25 years as an intellectual property (IP) attorney, Jane Remillard, Nelson Mullins patents and biotechnology IP senior partner, is well-versed in navigating drug development and antibody patent law. In this episode, Remillard speaks with moderator
Nimish Gera, Mythic Therapeutics vice president of biologics, about the intersection between science and law, the primary steps recommended to patent a scientific discovery, and how the antibody IP landscape has evolved in recent years. She also talks
about the importance of implementing a strategy regarding the number and types of antibody patents filed, her advice to anyone considering a career in IP law, and what to expect from the industry moving forward.
First posted on Oct 11, 2022
Jane Remillard, J.D., Patents and Biotechnology Intellectual Property Senior Partner, Nelson Mullins
Jane leads the Life Sciences Intellectual Property Team and has over 25 years of experience providing worldwide patent counseling
in the fields of biotechnology and pharmaceuticals. Jane’s practice focuses on developing and implementing effective IP strategies, building strong patent portfolios, and facilitating commercialization of products, particularly antibody-based
therapeutics, through all phases of development.
Nimish Gera, Ph.D., Vice President of Biologics, Mythic Therapeutics
Nimish Gera is the Vice President of Biologics at Mythic Therapeutics overseeing antibody discovery, engineering, optimization, and cell-based screening technologies
to generate antibody-drug conjugates. Nimish’s broad experience in biotech encompasses various modalities (monoclonal antibodies, bispecific antibodies, protein-fusions, and antibody-drug conjugates) and therapeutic areas (oncology, immuno-oncology,
autoimmune, and rare disease). Prior to Mythic, Nimish served as a project leader at Alexion Pharmaceuticals, where he led and managed diverse cross-functional project teams to lead two antibody discovery programs into development. Prior to Alexion,
Nimish helped establish discovery sciences functionality at Oncobiologics (now Outlook Therapeutics) and identified multiple lead candidates for the company’s platform. He earned a PhD in Chemical and Biomolecular engineering with a minor in
biotechnology at North Carolina State University and a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Guwahati.